HA-1
H is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1 H -derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore, an attempt was made to search for novel epitopes presented by HLA alleles other than those previously reported by generating CTL lines from patients undergoing HLA-identical, HA-1 disparate hematopoietic stem cell transplantation (hematopoietic SCT) by stimulation with a 29-mer HA-1 H peptide spanning a central polymorphic histidine (His). Two CTL clones established were found to be restricted by HLA-A*0206, which is the second or third most common HLA-A2 subtype worldwide. Epitope mapping revealed that the clones recognized the same nonameric peptide as A*0201-restricted HA-1 H , VLHDDLLEA. This epitope was unexpected, since it does not contain any preferred anchor motifs for HLA-A*0206. However, an HLA peptide binding assay revealed stronger binding of this peptide to A*0206 than to A*0201. Interestingly, HLA-A*0206-restricted CTL clones could lyse both HLA-A*0206 þ and HLA-A*0201 þ targets (including leukemic blasts) that express HA-1 H peptide endogenously, whereas an HLA-A*0201-restricted, HA-1
Introduction
Minor histocompatibility antigens (mHAs) are MHCbound peptides derived from cellular proteins, which are immunogenic because of their differential expression between the donor and recipient, most often due to a single nucleotide polymorphism (SNP). 1, 2 To date, significant efforts have been made to identify mHAs, particularly those specific for hematopoietic cells, since such mHAs have been speculated to contribute to the GVL effect following allogeneic stem cell transplantation (allogeneic SCT). Among these, HA-1, whose immunogenicity is controlled by a nonsynonymous SNP (dbSNP cluster ID: rs1801284) on the HMHA1 gene (GeneID: 23526), 3 has been studied most extensively since it can be used for immunotherapy of recurring hematological malignancies after HA-1-mismatched SCT. 4 The originally reported HA-1 mHA is an HLA-A*0201-restricted nonameric peptide carrying His (HA-1 H ) but not Arg (HA-1 R ) at position 3. 3 In an effort to expand the patient population for HA-1-based immunotherapy, a decameric peptide containing His at position 6 from the same polymorphic region has been identified as an mHA presentable by the HLA-B60 molecule. 5 The only other mHAs with selective expression in hematopoietic cells described to date are HA-2, Caucasian populations. While attempting to identify HLA alleles capable of presenting HA-1 mHAs other than the previously reported HLA-A*0201 and HLA-B60, 5 we unexpectedly found that HLA-A*0206 was able to present the nonameric peptide originally described as the A*0201-restricted HA-1 H mHA (VLHDDLLEA). These findings may be clinically beneficial for SCT recipients expressing HLA-A*0206, which accounts for 20-40% of HLA-A2 alleles in eastern Asia, by broadening the potential clinical relevance of an epitope that can be used for HA-1 mHAbased immunotherapy.
Materials and methods
Patients, cell culture and clones This study was approved by the Institutional Review Board of Aichi Cancer Center according to the Declaration of Helsinki. All blood samples were collected after written informed consent. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque (Pharmacia, Uppsala, Sweden). CD4 þ cells were isolated from donor PBMCs using anti-human CD4 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), expanded with 5 mg/ml PHA-L (Roche, Mannheim, Germany), 20 U/ml interleukin (IL)-2 (Chiron, Emeryville, CA, USA) and 20 ng/ml IL-7 (R&D Systems, Minneapolis, MN, USA) as previously reported, 16 and used as antigen presenting cells (APCs). CD3 þ cells were isolated from recipient PBMCs using anti-human CD3 microbeads (Miltenyi Biotec) and used as responder cells. CD34 þ leukemic cells were isolated from bone marrow specimens from acute myelocytic leukemia patients using anti-human CD34 microbeads (Miltenyi Biotec) and used as target cells. Epstein-Barr virus-transformed B lymphoblastoid cell lines (LCL) derived from donors, recipients and normal volunteers and the HLA class I-negative, LCL, 721.221 cell line 17 were maintained in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 10% fetal calf serum (IBL, Takasaki, Japan). LCLs were transduced with retroviral vectors carrying individual HLA cDNAs by a method described previously. 18 HLA cDNA-transfected cell lines are referred to by their 'cell line name/HLA allele' designation (e.g. 721.221/A*0201). EH6-CTL is a CD8 þ clone previously generated from an HLA-A*0201 þ and HA-1 R healthy individual.
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Synthetic peptides and in vitro CTL induction The peptide used for CTL induction consisted of 29 amino acids from the HA-1 polymorphic region with the histidine (underlined) in the middle (RFAEGLEKLKECVLHDDL-LEARRRRAHEC). All peptides were synthesized using standard Fmoc chemistry and dissolved in 100% DMSO. Donor-derived PHA-activated CD4 þ cells were pulsed with the 29-mer peptide (50 mg/ml) for 2 h at room temperature in AIM-V medium (Invitrogen, Carlsbad, CA, USA). CTL lines were generated from post-SCT CD3 þ cells (5 Â 10 4 ) by coculturing with irradiated (35 Gy) peptide-pulsed CD4 þ cells (5 Â 10 4 ) in 0.2 ml RPMI 1640 supplemented with 6% pooled human serum, 2 mM L-glutamine and penicillin/streptomycin (referred to as CTL medium) in the presence of recombinant human IL-6 (20 ng/ml, R&D Systems) and IL-12 (20 ng/ml, R&D Systems) in a 96-well round-bottomed plate. IL-2 (10 U/ml) was added on day 3. Individual wells were similarly restimulated weekly with irradiated, peptide-pulsed (10 mg/ml) donor CD4 þ cells without cytokines except for IL-2 (10 U/ml) on day 1. After the fourth stimulation, T cells in culture wells showing lytic activity to both recipient LCL and 29-mer peptide-pulsed donor LCL but not unpulsed donor LCL were combined and cloned by limiting dilution. Putative CTL clones were expanded as previously described 19 and frozen until use. HLA peptide binding assay A quantitative ELISA-based assay capable of measuring the affinity of the interaction between peptide and HLA was carried out as described previously, 20 with some modifications. In brief, purified recombinant HLA molecules in 8 M urea, 10 mM EDTA, 25 mM 2-(N-morpholino)-ethanesulfonicacid and 0.1 mM dithiothreitol were diluted to 4 mg/ml in refolding buffer containing 400 mM arginine, 100 mM Tris pH 8.0, 2 mM EDTA, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, 0.2 mM phenylmethyl sulfonyl fluoride (all from Sigma-Aldrich) and 2 mM purified b2-microglobulin (b2m) on ice. Ten-fold dilutions of each peptide were made with 100% DMSO in 96-well round-bottomed polypropylene plates, then 1 ml individual aliquots were transferred into new plates and 99 ml of the above HLA-b2m mixture was added to each MoAb (10 mg/ml) in 50 mM carbonate-bicarbonate buffer, pH 9.6 (Sigma), and kept overnight at 41C. After washing thrice with washing buffer containing 0.05% Tween 20 (Sigma-Aldrich) in PBS, the wells were blocked for 1 h. Just before the ELISA analysis, the reaction volume was diluted 10 times by PBS at 41C, and 50 ml/well of aliquots were transferred in duplicate to the W6/32 MoAb-coated plates. The plates were incubated for 2 h at room temperature and then washed six times. To detect properly refolded complexes, plates were incubated for 2 h at room temperature with 100 ml/well of a horseradish peroxidase-conjugated anti-human b2m MoAb (1:1000 dilution; DAKO, Copenhagen, Denmark), followed by washing as above. Finally, color development was performed with 3,3 0 ,5,5 0 -tetramethyl-benzidine as substrate (Sigma-Aldrich).
Tetramer construction and flow cytometric analysis HLA-A*0201 or HLA-A*0206 tetramers incorporating the HA-1 H peptide (VLHDDLLEA) were produced as described previously. 21 For staining, cells were incubated with the tetramers at a concentration of 20 mg/ml at room temperature for 15 min followed by FITC-conjugated anti-CD3 (Becton-Dickinson, San Diego, CA, USA) and Tricolor anti-CD8 MoAb (Caltag, Burlingame, CA, USA) on ice for 15 min. Cells were analyzed with a FACSCalibur flow cytometer and CellQuest software (Becton-Dickinson).
Determination of TCR variable (V)-gene usage TCR V-gene usage was assessed by RT-PCR using primers covering the entire families of functional TCR alpha (TCRAV) and beta (TCRBV) chains. Briefly, total RNA was extracted from individual CTL clones and cDNA was synthesized using M-MLV reverse transcriptase (Invitrogen) and primer p(dT) 15 (Roche) and used for PCR. For TCRBV usage determination, each reaction was carried out with an optimal concentration of sense primers specific for four or five different BV families and a primer specific for the constant region of TCRB. 22 For TCRAV usage determination, each reaction was carried out with a single sense primer specific for individual alpha families and a primer specific for the constant region of TCRA. 23 The PCR products were size-fractionated on 2% agarose gels. Subsequently, the complementarity-determining region 3 (CDR3) of each positive PCR product was sequenced with corresponding antisense primer as above. TCR V-gene usage was determined by the international ImMuno GeneTics information system (IMGT) software, IMGT/ V-QUEST (http://imgt.cines.fr). 24 Figure 1) . After the two lines were combined and cloned by limiting dilution, four putative CD8 þ CTL clones with the same specificity as the original T-cell lines were obtained (Table 1) .
Results

Induction
To test the HLA restriction of these putative clones, HLA class I-deficient 721.221 LCL were transduced with individual HLA class I cDNA of UPN022 and used as targets because this cell line was found to be positive for the HA-1 H allele. All four putative CTL clones demonstrated an identical pattern of HLA restriction, which was HLA-A*0206. Interestingly, these clones also lysed 721.221/ A*0201 efficiently (Table 1) . In contrast, EH6-CTL, a CD8 þ clone previously generated from an HLA-A*0201 þ and HA-1 R healthy individual, 18 was only able to lyse 721.221/A*0201 but not 721.221/A*0206, suggesting a higher degree of specificity. Out of the four putative clones from UPN022, 3B11-CTL and 4B1-CTL were found to be clonal by TCRBV usage analysis. Since the latter 4B1-CTL grew better, further experiments were carried out with it in comparison with EH6-CTL.
HLA restriction of 4B1-CTL was further tested using a panel of HLA-typed LCLs. As shown in Table 2 , 4B1-CTL lytic activity was dependent on the presence of the HA-1 H allele and either the HLA-A*0206 or HLA-A*0201 allele. UR6 LCL carrying the HA-1 H allele and HLA-A*0207 was not lysed.
Identification of the minimal epitope for the HLA-A*0206-restricted 4B1-CTL clone It has been shown that HLA-A*0206 has a single dominant anchor motif of Val at position 2 (P2), whereas A*0201 has two dominant anchor motifs, Leu at P2 and Val at P9. 25, 26 Because HLA-A2 molecules incorporate nonameric peptides preferentially, we searched for such nonamers with Val at P2 in the 29-mer peptide used in the stimulation. One peptide, CVLHDDLLE, which had a Leu at P3 as a strong anchor motif for A*0206 as well, was the only candidate to fulfill the requirement. We conducted peptide reconstitution assays using 4B1-CTL and LCL from an HLA-A*0206 þ , HA-1 R individual by pulsing the following peptides: CVLHDDLLE, its allelic variant CVLRDDLLE,
the original HA-1/A*0201 peptides (VLHDDLLEA and VLRDDLLEA) and decameric peptides of HA-1/A*0201 with a C-terminus extension of Arg (Figure 1a) . Unexpectedly, 4B1-CTL recognized the HA-1 H /A*0201 peptide at half maximal lysis of B1 nM and to lesser extent, its C-terminal extended decamer but could not recognize the predicted CVLHDDLLE nonamer at all.
To confirm that the HA-1 H /A*0201 peptide is indeed incorporated into the HLA-A*0206 molecule, an HLA peptide binding assay was carried out (Figure 1b) . Surprisingly, the HA-1 H /A*0201 peptide was incorporated into HLA-A*0206 10-fold better than into HLA-A*0201 as assessed by means of quantifying peptide-MHC-b2m complexes refolded successfully.
Next, recognition of the HA-1 H /A*0201 peptide in the context of the two HLA-A2 subtypes was assessed by cytotoxicity assay. As expected from the results shown in Tables 1 and 2 þ HA-1 R individual with a similar efficiency to that for 4B1-CTL. In addition, recognition of the HA-1 H /A*0201 peptide endogenously generated and presented by the two HLA-A2 subtypes was tested using the two CTL clones. As shown in Figure 1d , 4B1-CTL recognition of HA-1 H peptide presented by HLA-A*0206 was consistently better over the wide range of E:T ratio than both 4B1-CTL and EH6-CTL recognition of peptide presented by HLA-A*0201. These results indicate that the HA-1 H /A*0201 peptide, VLHDDLLEA, is presentable by both HLA-A2 subtypes and is sufficiently immunogenic. 4B1-CTL generated from an HLA-A*0206 þ SCT recipient showed less fine specificity in terms of scaffold molecules presenting VLHDDLLEA than EH6-CTL generated from an HLA-A*0201 þ individual.
Phenotypic and functional analyses using tetramers
We prepared HLA-A*0206 and HLA-A*0201 tetramers incorporating the HA-1 H /A*0201 peptide, VLHDDLLEA, and stained two CTL clones. As expected from the results shown in Table 2 , 4B1-CTL was stained not only with A*0206 tetramer but also with A*0201 tetramer, although mean fluorescence intensity with the latter tetramer was nearly three-fold lower (67.5 versus 194.5; Figure 2 , upper panels). In contrast, EH6-CTL was stained weakly with A*0206 tetramer (12.1%), while it was strongly stained with the cognate A*0201 tetramer (Figure 2 , lower panels). Next, we examined whether these tetramers could specifically block the recognition of target cells by the CTL clones (Figure 3a) . The lysis of 721.221/A*0206 LCL by A*0206-restricted 4B1-CTL was efficiently inhibited by the cognate A*0206 tetramer, whereas inhibition with A*0201 tetramer was less significant. Similarly, the lysis of 721.221/A*0201 LCL by A*0201-restricted EH6-CTL was more efficiently blocked with the cognate A*0201 tetramer. Interestingly, A*0206 tetramer appeared to be able to block the recognition of EH6-CTL as well as A*0201 tetramer at the highest E:T ratio tested, suggesting that crossreactivity can be observed under certain conditions (consistent with the low degree of lysis by EH6-CTL of A*0206 þ LCL seen at high peptide concentrations in Figure 1c ).
TCR variable region usage by HA-1
H -specific CTL clones It has been shown previously that all HLA-A*0201-restricted clones specific for HA-1 H peptides from three individuals use the conserved TCRBV gene, TCRBV6S9, 27, 28 corresponding to TCRBV7-9 by the IMGT classification. 24 We analyzed the variable and CDR3 usage of CTL clones, EH6, 4B1 and 3B11 (Table 3 , and data not shown). Interestingly, not only HLA-A*0201-restricted EH6 but also the HLA-A*0206-restricted 4B1 and 3B11 CTL clones used the TCRBV7-9, although TRAV usage was different. The CTL clones 4B1 and 3B11 were found to have identical TCRAV, TCRBV and CDR3 sequences (data not shown). It is to be noted that HLA-A*0206-restricted 4B1-CTL had the Leu-Val amino-acid pair in the TCRB N-region (Table 3, Cr and distributed to wells of 96-well round-bottomed plates, pulsed with serial dilutions of the indicated peptides for 30 min at room temperature, and then used as targets for HLA-A*0206-restricted 4B1-CTL in a standard 51 Cr release assay (E:T ratio of 10:1). Data shown are representative of two independent experiments and the experiments were performed in duplicate. All values with error bars indicated in all figures applicable are shown as mean7s.d. VLHDDLLEA was originally described as an HLA-A*0201-restricted HMHA1-derived mHA.
3 (b) Peptide-HLA binding assays were carried out as previously described 20 with some modifications (see Materials and methods). Purified HLA-A*0206 or HLA-A*0201 molecules were folded in folding buffer containing b2m and the serially diluted peptides indicated for 48-72 h. Amounts of properly folded HLA-A*0206 or HLA-A*0201 molecules were assessed by ELISA using plate-coated, conformation-dependent anti-HLA class I (clone W6/32) and horseradish peroxidase-tagged anti-b2m MoAbs. Cr-release assay was carried out at the various E:T ratios indicated. Data shown are representative of two independent experiments and the experiments were performed in duplicate.
HA-1
H is immunogenically presented by HLA-A*0206 H Torikai et al also shown to be shared by HLA-A*0201-restricted HA-1 H -specific CTL clones. 27 In vivo relevance of the HLA-A*0206-restricted HA-1 H peptide-specific CTL Since the HMHA1 gene is highly expressed in hematopoietic cells including hematopoietic malignancies, 3 we sought to examine whether 4B1-CTL could lyse leukemic CD34 þ cells carrying HA-1 H . As shown in Figure 3b , the CTL clone lysed not only HLA-A*0206 þ blasts but also HLA-A*0201 þ blasts as efficiently as UPN022 recipient-derived LCL. In contrast, the EH6-CTL recognized HLA-A*0201 þ but not HLA-A*0206 þ blasts (data not shown). Finally, we examined the in vivo presence of HLA-A*0206 þ -restricted, HA-1 H -specific T cells by means of tetramers. To this end, we stained PBMCs obtained at day 98 after SCT from a patient (UPN011) who was positive for both HLA-A*0201 and HLA-A*0206 and received HA-1 disparate marrow transplant from an unrelated, HLA-A, -B, -DR-matched donor (UPN022 PBMCs were no longer available). As shown in Figure 3c , minor populations of unstimulated CD8 þ cells were stained by HLA-A*0206 and HLA-A*0201 tetramers (0.06 and 0.18%, respectively) and with very low fluorescence intensity (compared to staining of the 4B1-CTL clone in Figure 2 , upper left panel). To ascertain that these minor tetramer þ populations were indeed HA-1 H specific, PBMCs were stimulated with peptide-pulsed APCs and assayed. After stimulation, individual tetramers detected around 15% tetramer
þ cells with subpopulations of cells (9.5 and 5.7%, boxed in Figure 3c ) staining as brightly as the 4B1-CTL and EH6-CTL clones, respectively. It is speculated that these populations might represent HA-1 H -specific CD8 þ T cells restricted by HLA-A*0206 and HLA-A*0201 molecules, respectively.
Discussion
Among human mHAs identified to date, HA-1 H is one of the most promising mHAs involved in GVL and graftversus-tumor effects due to its limited expression in hematopoietic cells 3 and some epithelial cancers. Clinical association of the emergence of CTLs specific for HA-1 H /A*0201 and the induction of remission following donor lymphocyte infusion in relapsed leukemia patients has been elegantly shown using tetramer analysis. 31 After successfully using a reverse immunological approach to identify HLA-B60 as the allele that presents the HMHA1-derived peptide KECVLHDDLL, we sought to identify other HLA alleles common in Asian populations associated with this mHA to expand the definition of the SCT recipient population that may benefit from immunotherapy based on HA-1 disparate transplantation.
In this study, we adopted two straightforward strategies. First, we used as responder cells post-SCT CD3 þ cells from patients receiving HA-1 R to HA-1 H disparate SCT. Because these cells have potentially been primed in vivo by certain HLA molecules that are able to present endogenously processed mHA peptides, such memory T cells should be more easily expanded than naı¨ve T cells. Second, we used a long (29-mer) peptide with the polymorphic His at the middle to cover the possibility that putative epitope(s) are presented not only by HLA class I but also by class II. This strategy is based on an epitope mapping approach using overlapping peptides, which has been applied to identifying epitopes from an entire protein sequence of interest regardless of HLA type, 32, 33 although up to 20-mer peptides are recommended for efficient stimulation for an intracellular cytokine staining approach. 33 As a result of induction and cloning attempts from four post-SCT blood samples, we obtained CTL clones that could recognize the HA-1 H / A*0201 peptide, VLHDDLLEA, which was endogenously processed and presented on HLA-A*0206 molecules. In addition, the in vivo presence of a bona fide HA-1 H -specific T cell response was indeed confirmed by tetramer analysis. These results support the recent report demonstrating that not only professional APCs but also non-professional APCs such as B cells or even peripheral blood lymphocytes can process and present properly trimmed peptides in the context of HLA class I, although the mechanism involved has not been fully elucidated. 34 Based on our observations, it is likely that PHA-activated CD4 þ blasts can handle long peptides up to 29 amino acids in length. However, further studies into whether CD4 þ blasts may also present processed antigens on class II molecules and stimulate cognate responder CD4 þ T cells are necessary. Finally, whether HLA-A*0206 is the sole allele that can present Effector: EH6-CTL (A*0201) Abbreviations: CTL ¼ cytotoxic T lymphocyte; HLA ¼ human leukocyte antigen; TCR ¼ T-cell receptor for antigen; TCRA ¼ TCR alpha; TCRB ¼ TCR beta. a 4B1-CTL and 3B11-CTL were considered to be derived from the same origin based on their complementarity-determining region 3 (CDR3) sequence. Nomenclature is based on the international ImMunoGeneTics (IMGT) information system. The LV amino-acid pair in the TCRB N-region, which was also shown to be interindividually shared by HLA-A*0201-restricted HA-1 H -specific CTL clones, 27 is underlined.
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